There are currently 134 clinical trials in Eugene, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Research Institute, Willamette Valley Cancer Institute and Research Center, University of Oregon and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
NCT05615844
Recruiting
The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participants will be randomized to receive either an antibiotic bead pouch or negative pressure wound therapy (NPWT) for their temporary open fracture wound management. Outcomes will be assessed at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome will be a composite outcome to evaluate clinica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Slocum Center, Eugene, Oregon
Conditions: Open tíbia Fracture
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Triple Negative Breast Cancer
Register for Updates
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Chase Gardens Surgery Center, Eugene, Oregon +1 locations
Conditions: Lumbar Spinal Stenosis
Register for Updates
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055
Recruiting
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Pacific Sports and Spine, LLC, Eugene, Oregon
Conditions: Pain
Register for Updates
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
NCT06524375
Recruiting
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135
Recruiting
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Oncology Associates of Oregon, Eugene, Oregon
Conditions: Multiple Myeloma
Register for Updates
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262
Recruiting
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Pacific Sports and Spine, Eugene, Oregon
Conditions: Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Register for Updates
School-based Paraeducator Education for Engagement at Recess
NCT06559267
Recruiting
The purpose of the proposed three-site study is to test whether an educator-level implementation strategy, coaching, with or without a school-level implementation strategy, school-based teams, will maximize paraeducators' use (fidelity and sustainment) of an evidence-based social engagement intervention, Remaking Recess (RR). RR aims to improve peer related social skills for autistic students and their non-autistic peers who are socially isolated or peripheral and need support during recess.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
08/11/2025
Locations: University of Oregon, Eugene, Oregon
Conditions: Autism Spectrum Disorder, Neurodevelopmental Disorders
Register for Updates
Patient Retrospective Outcomes (PRO)
NCT01550575
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Pacific Sports and Spine, LLC, Eugene, Oregon
Conditions: Chronic Pain
Register for Updates
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153
Recruiting
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/08/2025
Locations: Verum Research, LLC, Eugene, Oregon
Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Register for Updates
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder
NCT06256367
Recruiting
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with significant morbidity and mortality defined by episodes of mania and depression (or symptoms of both at once, known as mixed features). This prospective, observational study will examine effectiveness, functioning and quality of life outcomes in adult patients with BP-I experiencing a major depressive episode (with or without mixed features) requiring treatment and initiating treatment with cariprazine. It will exa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Betts Psychiatric, PC /ID# 259737, Eugene, Oregon
Conditions: Bipolar I Disorder
Register for Updates
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06806033
Recruiting
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Oncology Associates of Oregon, P.C, Eugene, Oregon
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates